Literature DB >> 8478940

Interactions between morpholinyl anthracyclines and DNA. The crystal structure of a morpholino doxorubicin bound to d(CGTACG).

M Cirilli1, F Bachechi, G Ughetto, F P Colonna, M L Capobianco.   

Abstract

Anthracycline antibiotics daunomycin and adriamycin are among the most widely used in cancer chemotherapy and DNA is believed to be the primary target of their biological action. The crystal structure of a morpholino derivative of adriamycin bound to the DNA hexamer d(CGTACG) has been determined at 1.5 A resolution. The complex crystallizes in space group P1 with unit cell dimensions a = 18.01 A, b = 18.83 A, c = 27.65 A, alpha = 92.6 degrees, beta = 100.5 degrees, gamma = 94.9 degrees and there are two drug molecules bound per duplex. Morpholino derivatives differ greatly from their parent compounds in their biological and pharmacological properties. Structural comparison of this complex with the series of previously reported anthracycline-DNA complexes offers an opportunity for studying relationships between structure and function. The anthracycline chromophore intercalates at the CpG step and DNA distortions from a B-type conformation are similar to those observed in the other DNA-anthracycline complexes. Interactions between drug and DNA show no differences at the intercalation site, while in the minor groove they are significantly affected by the presence of the bulky morpholinyl moiety on the anthracycline amino sugar. The binding site involves four base-pairs and the absence of a positive charge on the amino sugar appears to influence the hydration pattern on both grooves. The two halves of the duplex are symmetrically related by a non-crystallographic 2-fold axis but they are not equivalent. In one half, one magnesium cluster bridges both drug and DNA, further stabilizing the complex.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478940     DOI: 10.1006/jmbi.1993.1208

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  8 in total

1.  Light-controlled release of caged doxorubicin from folate receptor-targeting PAMAM dendrimer nanoconjugate.

Authors:  Seok Ki Choi; Thommey Thomas; Ming-Hsin Li; Alina Kotlyar; Ankur Desai; James R Baker
Journal:  Chem Commun (Camb)       Date:  2010-02-06       Impact factor: 6.222

2.  Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.

Authors:  Andrey E Shchekotikhin; Lyubov G Dezhenkova; Vladimir B Tsvetkov; Yuri N Luzikov; Yulia L Volodina; Victor V Tatarskiy; Anastasia A Kalinina; Michael I Treshalin; Helen M Treshalina; Vladimir I Romanenko; Dmitry N Kaluzhny; Michael Kubbutat; Dominique Schols; Yves Pommier; Alexander A Shtil; Maria N Preobrazhenskaya
Journal:  Eur J Med Chem       Date:  2016-02-04       Impact factor: 6.514

3.  Synthesis and binding properties of conjugates between oligodeoxynucleotides and daunorubicin derivatives.

Authors:  A Garbesi; S Bonazzi; S Zanella; M L Capobianco; G Giannini; F Arcamone
Journal:  Nucleic Acids Res       Date:  1997-06-01       Impact factor: 16.971

4.  Ligand binding mode to duplex and triplex DNA assessed by combining electrospray tandem mass spectrometry and molecular modeling.

Authors:  Frédéric Rosu; Chi-Hung Nguyen; Edwin De Pauw; Valérie Gabelica
Journal:  J Am Soc Mass Spectrom       Date:  2007-03-28       Impact factor: 3.109

5.  Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG).

Authors:  I Berger; L Su; J R Spitzner; C Kang; T G Burke; A Rich
Journal:  Nucleic Acids Res       Date:  1995-11-11       Impact factor: 16.971

6.  Multi drug resistance-dependent "vacuum cleaner" functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density.

Authors:  Cyril Rauch; Alain Pluen
Journal:  Eur Biophys J       Date:  2007-01-09       Impact factor: 2.095

7.  DNA-Destabilizing Agents as an Alternative Approach for Targeting DNA: Mechanisms of Action and Cellular Consequences.

Authors:  Gaëlle Lenglet; Marie-Hélène David-Cordonnier
Journal:  J Nucleic Acids       Date:  2010-07-25

8.  Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression.

Authors:  Yuan Huang; Donghai Jiang; Meihua Sui; Xiaojia Wang; Weimin Fan
Journal:  Oncol Rep       Date:  2016-12-14       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.